News
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early
AstraZeneca (AZ) and Daiichi Sankyo have posted new data from Phase I/II trials evaluating their respective antibody drug conjugates (ADCs) Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan.